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Nanomachines oﬀer considerable promise for the treatment of diseases. The ability of man-made
nanomotors to rapidly deliver therapeutic payloads to their target destination represents a novel
nanomedicine approach. Synthetic nanomotors, based on a multitude of propulsion mechanisms, have
been developed over the past decade toward diverse biomedical applications. In this review article, we
journey from the use of chemically powered drug-delivery nanovehicles to externally actuated (fuel-free)
drug-delivery nanomachine platforms, and conclude with future prospects and challenges for such
practical propelling drug-delivery systems. As future micro/nanomachines become more powerful and
functional, these tiny devices are expected to perform more demanding biomedical tasks and beneﬁt
diﬀerent drug delivery applications.Introduction
Drug delivery needs
Drug delivery technology is an area of enormous importance to
health care, and aims at addressing the deciencies of
conventional means for administering drugs.1,2 The need for the
development of innovative technologies to improve the delivery
of therapeutic agents in the body has been widely recognized.
Considerable research eﬀorts have thus been directed over the
past 15 years to the development of targeted drug delivery
systems aimed at preventing and treating debilitating diseases.3ei Gao received his PhD in
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494Such delivery platforms promise to address several key issues,
including low therapeutic eﬃcacy and signicant negative side
eﬀects by delivering a drug where the medication is needed,
while sparing healthy parts of the body.4,5 New technologies are
also needed for delivering therapeutic agents to areas of the
body that are currently inaccessible to current delivery methods
and for improving tissue penetration.Towards nanomedicine
Nanotechnology-enabled drug delivery systems have received
considerable interest owing to their major impact on the
treatment of diseases.6,7 The promise of such nanotechnology-
based systems is to deliver a drug selectively to the target tissues
and cells with increased eﬃcacy while reducing side eﬀects.3 AJoseph Wang is a Distinguished
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View Article Onlinewide range of nanomaterial-based systems have thus been
developed for drug delivery applications, including liposomes,
polymeric nanoparticles, dendrimers, polymersomes, nano-
emulsions.1,2 Signicant progress has been made towards
improving the therapeutic eﬃcacy of drug-loaded nano-
particles, including extended drug systemic circulation lifetime,
improved the solubility of poorly water-soluble drugs, co-
delivery of two or more drugs or of therapeutic and imaging
agents within the same particle (i.e., “theranostics”), and
controlled or triggered release of the encapsulated drugs. While
functionalizing the particle surface with targeting ligands can
result in accumulation around tumors, oﬀ-targeting (and the
corresponding adverse eﬀect) remains a major challenge.
Another challenge of common drug delivery vehicles is the lack
of power necessary for penetrating tissue and cellular barriers.
Deep tissue penetration and cellular interaction thus represents
another important goal. To achieve such active targeting and
deliver payloads to predetermined locations in the body, future
generation drug delivery vehicles may need to incorporate
propulsion and navigation capabilities. Nanoshuttles, precisely
guided by a physician, have the potential to transport thera-
peutic agents directly to diseased tissues, and to access nearly
every site of the human body through blood vessels, indepen-
dent of the blood ow, thereby improving the therapeutic eﬃ-
cacy and reducing systemic side eﬀects of highly toxic drugs.Nanomotors for drug delivery
The use of nanomotors to power nanomachines is currently a
research area of tremendous activity due to a wide range of
potential applications.8–17 Synthetic nanomotors, based on a
multitude of propulsion mechanisms, have thus been devel-
oped over the past decade.8–10,18 While most of this attention
has been given to chemically powered catalytic micro-
motors,19–23 many important applications (particularly in vivo
biomedical ones) require the elimination of the fuel require-
ments toward biocompatible propulsion mechanisms. Eﬀorts
in this direction have led to the fuel-free locomotion of
magnetically driven nanoswimmers,24–28 or acoustically
propelled devices.29–31 Major advances in nanomotor tech-
nology, including the design of powerful multifunctional
machines, advanced motion control and cargo towing capa-
bilities, have facilitated diﬀerent biomedical applications
ranging from cell sorting32 to DNA hybridization.33 The
substantial progress towards using functionalized nano-
motors for eﬃcient cargo transport and release paves the way
to their drug-delivery applications. The targeted delivery of
therapeutic cargoes represents a major future application of
synthetic micromotors.16 Such nanomachine-based drug
delivery systems are highly attractive platforms for eﬃcient
delivery of therapeutic payloads to targeted sites, and could
address some of the obstacles of current drug delivery systems.
Unfortunately, there is no comprehensive review published on
using synthetic micro/nanomachines for drug delivery
platforms.
In this review we highlight recent research eﬀorts aimed at
developing man-made nanomachines for drug deliveryThis journal is © The Royal Society of Chemistry 2014applications and give an outlook on current challenges and
emerging trends. Table 1 summarizes recent progress of drug
delivery based on diverse nanomotors powered by diﬀerent
mechanisms. These new drug-delivery nanoshuttles are dis-
cussed in the following sections, along with related opportu-
nities and challenges.Catalytically powered micro/
nanomotors for targeted drug delivery
Catalytically powered micro/nanoscale motors rely on the
catalytic decomposition of a solution-borne fuel, usually
hydrogen peroxide, on a platinum surface.19–23 Such fuel-driven
motors possess a relatively high power essential for performing
diﬀerent biomedical tasks involving cargo towing.46 This force is
reected by a remarkable speed that can exceed 1000 body-
lengths s1.47 Motion control is another important requirement
for targeted drug delivery. The directionality of catalytic micro/
nanoscale motors can be readily controlled (commonly via
magnetic guidance) and their speed can be regulated using
diﬀerent stimuli.48 Tremendous progress has been made on
cargo-carrying catalytic nanomotors based on diﬀerent loading
and unloading mechanisms.49 These advances have facilitated
eﬀorts aimed at using a variety of catalytic nanomotors (based
on wire, sphere or open-tube congurations) for targeted drug
delivery.
Wang, Zhang and coworkers demonstrated the rst
example of using man-made micromotors for the transport
and release of drugs.34 This pioneering study illustrated that
catalytic nanowire shuttles can readily pickup drug-loaded
poly D,L-lactic-co-glycolic acid (PLGA) particles and liposomes
and transport them over predetermined routes towards target
destinations. Powerful alloy or CNT-based nanowire motors
have been used to increase the force necessary to transport
‘heavy’ therapeutic cargos. These nickel-containing motors
captured the iron-oxide encapsulated PLGA and liposome drug
nanocarriers through magnetic interactions. The nanomotors
can thus pickup, transport and release varying sized drug
carriers towards predetermined destinations. Fig. 1 displays
scheme (A) and time-lapse images (B) of such dynamic
capture, transport and release of doxorubicin (DOX)-loaded
PLGA nanoparticles using a catalytic Ni/(Au50/Ag50)/Ni/Pt
nanowire motor. In comparison with the PLGA particles,
transport of the drug-loaded liposome is relatively slower due
to its large size.
Wu et al. reported the preparation of a well-dened multi-
layer tubular polymeric nanomotor through the nanoporous
template-assisted layer-by-layer (LbL) assembly.35 Platinum
nanoparticles (Pt NPs), assembled into the inner surface of LbL-
assembled nanotubes, provided the catalytic decomposition of
the hydrogen peroxide fuel essential for the bubble propulsion.
These nanorockets can serve as autonomous motors as well as
smart cargos, performing drug loading, targeted transportation
and remote-controlled release in the vicinity of cells and tissues.
The uorescent anticancer drug doxorubicin was loaded onto
the nanorockets through encapsulation. An ultrasound (US)Nanoscale, 2014, 6, 10486–10494 | 10487
Table 1 Recent progress on drug delivery using micro/nanomotors based on a multitude of propulsion mechanisms and designs
Types of motors Type of drug/model drug Attach/release References
Catalytically powered
nanomotors
Ni/(Au50/Ag50)/Ni/Pt Doxorubicin in PLGA and
liposome nanoparticles
Magnetic interaction Kagan et al.34
LbL self-assembled
PSS/PAH capsule
FITC–dextran Encapsulation by varying
solvent polarities
Wu et al.35
LbL polymer multilayer
CHI/ALG nanorockets
Doxorubicin LbL encapsulation/
ultrasound triggered
release
Wu et al.36
Janus mesoporous silica
nanomotors
Doxorubicin Adsorption of porous
silica/endocytosis
Xuan et al.37
LbL PSS/PAH catalase
based capsules
Doxorubicin Encapsulation/NIR laser
triggered release
Wu et al.38
AgNP-decorated
polycaprolactone single
crystal
Fluorescent rhodamine B
isothiocyanate
Covalent link/disassembly Li et al.39
Micromotors-powered by
alternative fuels
Mg based microsphere
motors
FITC Temperature-induced
“breath-in” eﬀect/
temperature triggered
release
Mou et al.40
Zinc based micromotors Silica and gold particles Plating encapsulation/
dissolution in an acidic
environment
Sattayasamitsathit et al.41
Magnetic nanomotors Flexible nanowire motors Doxorubicin loaded in
PLGA nanoparticles
Magnetic interaction/
diﬀusion
Gao et al.42
Helical swimmer Calcein loaded in
liposome particles
Electrostatic interaction/
fusion of the cationic
vesicles or endocytosis
Mhanna et al.43
Helical swimmer Rhodamine B and calcein Electrostatic interaction/
temperature triggered
release
Qiu et al.44
Ultrasound nanomotors Au/Ni/Au/PPy nanowire
motor
Brilliant green Electrostatic interaction/
pH triggered release
Garcia-Gradilla et al.31
Porous Au–Au–Ni–Au
nanowire
Doxorubicin and brilliant
green
Electrostatic interaction/
NIR triggered release
Garcia-Gradilla et al.45
Fig. 1 Transport and release of PLGA drug carriers by catalytic
nanowire motors. Schematic (A) and microscopic time lapse-images
(B) depicting the dynamic pick-up (a), transport (b), and release (c) of
drug-loaded PLGA particles using a nanoshuttle. (Reproduced from
ref. 34, Wiley 2010.)
Fig. 2 (A) Self-assembled polymer multilayer nanorockets based on a
template-assisted layer-by-layer (LBL) technique can propel chemi-
cally in the presence of a hydrogen peroxide fuel. These motors can
perform drug loading, targeted transportation, and triggered drug
release by an external physical stimulus in a controlled manner. (B) The
DIC (a and d), the corresponding CLSM (b and e), and SEM images (c
and f) of a (CHI/ALG)4–DOX–(ALG/CHI)2–Fe3O4–(CHI/ALG)14–PtNP
nanorocket before (a–c) and after (d–f) ultrasound treatment in vitro
and continuous cultivation of the HeLa cells for 3 h. (Reproduced from
ref. 35, Wiley 2013.)
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View Article Onlineeld was used to trigger the breakage of the outer shell of the
LbL assembled polyelectrolyte multilayer microcapsules and
release the encapsulated drugs. The images in Fig. 2 display
(alginate (ALG)/chitosan (CHI))4–DOX–(ALG/CHI)2–Fe3O4–(CHI/
ALG)14–Pt NP nanorockets attached to the outer surface of HeLa10488 | Nanoscale, 2014, 6, 10486–10494 This journal is © The Royal Society of Chemistry 2014
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View Article Onlinecancer cells. Diﬀerential interference contrast (DIC), confocal
laser scanning microscopy (CLSM), scanning electron micros-
copy (SEM), and atomic force microscopy (AFM) images show
the corresponding results before and aer ultrasonic treatment.
In comparison with the image before ultrasonic treatment
(Fig. 2Bb), the red uorescence from DOX in the CHI/ALG
multilayer nearly disappeared (Fig. 2Be), indicating that most of
DOX molecules have been released through the ultrasound
irradiation. Similar concepts were also demonstrated in LBL
capsule based micromotors. Wu et al. reported also the use of
dendritic Pt-nanoparticles or catalase-modied polyelectrolyte
capsules as micromotors as well as carriers for drug delivery.36,38
Fluorescein isothiocyanate–dextran (FITC–dextran) model
drugs or doxorubicin have been loaded onto these microcap-
sules by encapsulation.
Another recent work from the same Chinese group
described a new self-propelled Janus silica nanomotor which
can also serve as the drug carrier for intracellular drug
delivery.37 As illustrated in Fig. 3, this peroxide-propelled
catalytic Janus nanomotor is based on mesoporous silica
nanoparticles (MSNs) with chromium/platinum metallic caps.
MSNs oﬀer an exceptionally high surface area, which enables
the loading of diverse cargoes. The DOX drug was loaded into
mesoporous pore channels of Janus MSN motors by physical
adsorption, and then covered with an egg phosphatidylcholine
(PC) bilayer. Intracellular localization and drug release
experiments in vitro have indicated that the amount of Janus
MSN nanomotors entering the cells is more than control MSNs
with the same culture time and particle concentrations,
meanwhile anticancer drug doxorubicin hydrochloride loaded
in Janus MSNs can be slowly released in the cells by biodeg-
radation of the lipid bilayers.
Other recent studies hold considerable promise for a variety
of biomedical applications. For example, Sanchez et al. reported
the use of self-propelled rolled-up microtubes to drill and
embed themselves into biomaterials such as cells which can be
potentially used to address the endosome escape challenge and
deliver the drug or gene inside the cell.50 Another study by Wu
et al.51 demonstrated that by taking advantages of photothermal
eﬀects, PtNP-modied polyelectrolyte multilayer microtube
engines can be used for targeted recognition and subsequent
killing of cancer cells.Fig. 3 (A) Synthetic procedure for the preparation of Janus MSN
nanomotors, as well as subsequent drug loading, lipid bilayer func-
tionalization, transportation, and drug release. (B) DOX release from
egg PC modiﬁed Janus MSN nanomotors inside HeLa cells following:
(a) 0, (b) 1, (c) 2, and (d) 3 h. The images are overlays of ﬂuorescence
and DIC channels. Scale bars, 10 mm. (Reproduced from ref. 37, Wiley
2014.)
This journal is © The Royal Society of Chemistry 2014Micromotors powered by alternative
fuels for drug delivery
Although major progress has been made on drug delivery based
on catalytic micro/nanomotors, current reliance on the
common hydrogen peroxide fuel greatly hinders practical
biomedical applications of catalytic micromotors. In particular,
in vivo drug delivery applications would require the use of body
uids or their constituents as the powering fuel. Recent eﬀorts
have been directed at expanding the scope of fuels for synthetic
nanomotors by exploring the use of natural biouids as the fuel
source, thus obviating the need for external chemical fuels.52–56
For example, Gao et al. described an acid-driven polyaniline/
zinc microtube rocket that can propel autonomously and eﬃ-
ciently in gastric acid, and thus can be operated in the stomach
environment.52 Reports of the use of glucose-powered enzyme-
based carbon swimmers are also promising in this respect,
although the propulsion mechanism is based on current ow,
and was shown to diminish at high salt concentrations.57
Of particular interest for practical drug delivery applications
are recently developed water-drivenmicromotors that utilize the
magnesium–water reaction for the propulsion.55,56 These
magnesium-based Janus microsphere motors consist of biode-
gradable magnesium microparticles coated with a gold or
platinum patch. Such water-driven micromotors utilize macro-
galvanic corrosion and chloride pitting corrosion processes to
generate hydrogen bubbles that propel the microparticles. This
eliminates the need for external fuels and oﬀers eﬃcient pro-
pulsion in untreated high-salt aquatic media which is particu-
larly attractive for in vivo drug delivery applications. Another
water-driven micromotor explores Janus particles based on the
Al–Ga alloy for eﬃcient hydrogen bubble propulsion through a
process called ‘liquid metal enbrittlement’,54 but lacks the
biocompatibility of magnesium-based micromotors. Additional
eﬀorts should be devoted to extending the lifetime of these
water-powered micromotors, along with proper surface func-
tionalization, for addressing the requirements of practical drug
delivery.
Mou et al. described recently a biocompatible drug-loaded
magnesium-based Mg/Pt–poly(N-isopropylacrylamide) (PNI-
PAM) Janus micromotor (Fig. 4).40 Such water-powered micro-
motors display an eﬃcient autonomous motion in simulated
body uid (SBF) or blood plasma without any additives or fuels.
It oﬀers also attractive capabilities of loading, transporting and
delivering drug molecules by taking advantages of the partial
surface-attached thermoresponsive PNIPAM hydrogel layers.
The drug releasing process from the micromotor can be
controlled by the environmental temperature due to the
‘squeeze’ eﬀect. Hemolysis assay has suggested that such
micromotors and their autonomous motion have a negligible
inuence on the red blood cells (RBCs, highly hemocompatible)
and are friendly to organisms.
Combination therapy oﬀers several distinct advantages for
disease treatment (e.g., high eﬃciency, synergistic eﬀects and
reversal of drug resistance) compared to normal single drug
therapy.6,58 Such combinatorial drug delivery may require newNanoscale, 2014, 6, 10486–10494 | 10489
Fig. 4 (A) Schematic demonstration of the drug (a and b) loading, (c)
transporting, and (d) releasing behaviors of the Mg/Pt–PNIPAM Janus
micromotors. (B) Fluorescent images representing the drug release
from the Mg/Pt–PNIPAM Janus microsphere motor (a) and the
normalized average cumulative drug release proﬁles (b) at 20 and
37 C versus time. Scale bars: 10 mm. (Reproduced from ref. 40,
American Chemical Society 2014.)
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View Article Onlinevehicles that enable co-encapsulation of diﬀerent drugs, active
targeting, and/or temporally controlled release. A recent work
from our laboratory illustrated a fully loaded multi-cargo zinc
based micromotor which can be potentially used for combina-
torial delivery (Fig. 5).41 Such an acid-powered bubble-propelled
micromotor possesses several distinct functions for potential
biomedical use. These include remarkably high loading
capacity, combinatorial delivery of a multitude of cargoes,
autonomous release of encapsulated payloads, and self-
destruction. Such multifunctional zinc-based micromotors,
prepared by dual-templating nanofabrication, can move rapidly
in an acidic environment and transport the fully loaded cargoes
with a speed of 110 mm s1. As the zinc body is oxidized and
dissolved by the acid fuel, the diﬀerent cargoes are released
autonomously and the motors are self-destroyed, leavingFig. 5 SEM images and energy-dispersive X-ray spectroscopy (EDX)
analysis of fully loaded dual-cargo Zn micromotors towards combi-
natorial therapy. (a–d) Zn micromotors encapsulated with 500 nm
SiO2 particles. (e–h) control Zn micromotors without the SiO2 parti-
cles. Scale bar, 0.5 mm (b) and (f), 1 mm (a) and (e), and 2 mm (c), (d), (g)
and (h). (Reproduced from ref. 41, Wiley 2014.)
10490 | Nanoscale, 2014, 6, 10486–10494behind no harmful chemical agents. This attractive concept can
be readily expanded to simultaneous encapsulation of a wide
variety of payloads, possessing diﬀerent biomedical functions
such as therapy, diagnostics, and imaging, hence opening up
new drug delivery opportunities.
Magnetic micro/nanomotors for drug
delivery
To address the limitations of fuel-driven micromotors and
enhance biocompatibility, several groups have been exploring
fuel-free micro/nanomachine propulsion mechanisms,
including the utilization of magnetic,24–28 electrical,59–61
optical,62 or ultrasound29–31 elds. Magnetically driven nano-
motors, inspired by nature swimming microorganisms, are
particularly promising for use in a variety of in vivo biomedical
applications.12 Such micromotors can swim under externally
applied magnetic elds in various biouids, and perform
complex maneuvers while obviating fuel requirements.
Magnetic actuation is suitable for in vivo applications since the
required eld-strengths are harmless to humans. Ghosh et al.
reported recently the rst successful “voyage” of magnetic
nanomotors, based on conformal ferrite coatings, in human
blood.63 Such magnetic “nanovoyagers” were shown to be
cytocompatible with mouse myoblast cells. Magnetically actu-
ated micromachines are thus currently being explored exten-
sively as promising platforms for controlled in vivo drug delivery
applications.
Gao et al. reported the rst example of directed delivery of
drug-loaded magnetic polymeric particles using magnetic
nanoswimmers.42 The fundamental mechanism of the cargo-
towing ability and the hydrodynamic features of these exible
nanowire motors have been discussed. The eﬀect of the cargo
size on the swimming performance was evaluated experimen-
tally and compared to a theoretical model, emphasizing the
interplay between hydrodynamic drag forces and boundary
actuation. Potential applications of these cargo-towing nano-
swimmers were demonstrated using the directed delivery ofFig. 6 Drug delivery to HeLa cells using ﬂexible magnetic nano-
swimmers in cell-culture media. Scheme (A) and microscopic time-
lapsed images (B) depicting the process as a ﬂexible magnetic Ni–Ag
nanowire motor (a) capturing the doxorubicin-loaded magnetic
poly(D,L-lactic-co-glycolic acid) (PLGA) particle in the loading reservoir
(b), transporting it through the microchannel (c), approaching the
target cell (d), sticking onto the target cell, and releasing the drug (e).
(Reproduced from ref. 42, Wiley 2014.)
This journal is © The Royal Society of Chemistry 2014
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View Article Onlinedrug-loaded microparticles to HeLa cancer cells in biological
media. Fig. 6 illustrates the schematic and experimental results
of using the magnetic nanowire swimmers for transporting of
target iron oxide/doxorubicin-encapsulated PLGA particles
through a microchannel from the pick-up zone to the release
microwell.
As was illustrated by Nelson's group in ETH, magnetically
actuated helical micromachines hold considerable promise for
diverse biomedical applications.64,65 The Swiss team developed
the articial bacterial agella (ABFs) which are capable of per-
forming precise 3D navigation in uids under rotatingmagnetic
elds and are harmless to cells and tissues.28 They reported the
successful functionalization of titanium-coated ABFs with
temperature-sensitive dipalmitoyl phosphatidylcholine (DPPC)-
based liposomes. The ability to load both hydrophilic and
hydrophobic drugs and to release the cargo was illustrated. The
functionalized ABFs (f-ABFs) can be used to incorporate both
hydrophilic and hydrophobic drugs. The preparation of lipo-
some-functionalized microdevices was demonstrated for
remotely controlled single-cell drug delivery. These liposome-
functionalized articial bacterial agella displayed corkscrew
swimming in 3D with micrometer positioning precision by
applying an external rotating magnetic eld. The devices are
also capable of delivering water-soluble drugs to single cells in
vitro (Fig. 7A).43 Thermally triggered release of calcein (a
common drug analog) from f-ABFs was demonstrated
(Fig. 7B).44 The uorescent signals on f-ABFs greatly decreasedFig. 7 Magnetically propelled helical microswimmer for drug delivery.
(A) f-ABF swimming and calcein delivery to single cells. (a) A repre-
sentative time-lapse follow-up of the swimming of functionalized
artiﬁcial bacterial ﬂagella (f-ABF) coated with calcein-loaded lipo-
somes. (b) Representative calcein delivery from f-ABF to single cells at
low magniﬁcation (left), high magniﬁcation of calcein delivery (middle)
and calcein delivered to cells after removing the f-ABF (right).
(Reproduced from ref. 43, Wiley 2014.) (B) Calcein release from DPPC/
MSPC-functionalized ABFs at 33, 37 and 41 C, respectively. The upper
three pictures are ﬂuorescence images, and the lower three pictures
are the combined images of ﬂuorescence and bright ﬁelds. (Repro-
duced from ref. 44, Elsevier 2014.)
This journal is © The Royal Society of Chemistry 2014upon increasing the temperature from 37 to 41 C and the
uorescence intensity of the background increased accordingly,
indicating the signicant release of entrapped calcein from the
DPPC/monostearoyl phosphatidylcholine (MSPC) liposomes at
41 C. These f-ABFs oﬀer considerable potential for drug
delivery.
Despite the signicant progress of the nanomotor design
and our new understanding of the ability of magnetic micro-
motors to transport cargo, several key challenges still exist for
their practical in vivo use. While eliminating the fuel require-
ments, attention must be given also to the preparation of more
biocompatible magnetic nanoswimmers. A protective coating
around a magnetic nanomotor is essential to prevent etching of
the magnetic material by blood components. Cleavable linkers,
responsive to tumor microenvironments, are desired to enable
an autonomous release of the therapeutic payload to the target
site. Signicant challenges remain for translating these initial
proof-of-concept studies into practical drug delivery applica-
tions. Eventually, such magnetically driven fuel-free nano-
shuttles are expected to provide an attractive approach for
delivering drug cargos to predetermined destinations in a target
specic manner.Ultrasound-powered micro/
nanomotors for drug delivery
Ultrasound has found extensive applications in medicine, and
holds considerable promise for driving micromotors in bio-
logical uids.66,67 Recent eﬀorts by the teams of Mallouk's
group29,68 and our team30,31 have illustrated the use of possibility
of using ultrasound for propelling gold-nanowire and tubular
motors in biologically relevant environments.
Garcia-Gradilla et al. described recently the use of ultra-
sound-driven nanowire motors based on the nanoporous gold
segment for increasing the drug loading capacity.45 The new
highly porous nanomotors, prepared by dealloying a Au–Ag
alloy segment, oﬀer a tunable pore size, high surface area, and
high capacity for the drug payload. The drug doxorubicin was
loaded within the nanopores via electrostatic interactions with
an anionic polymeric coating. Ultrasound-driven transport of
the loaded drug toward cancer cells was followed by near-Fig. 8 (A) Schematic of the ultrasound-driven movement of the drug-
loaded nanoporous Au nanowire motors and triggered release of the
drug around a cancer cell. (B) NIR-triggered anticancer drug DOX
release as a function of irradiation time using PSS-modiﬁed PAu
nanomotors (a) and Au nanomotors (b). (Reproduced from ref. 45,
Wiley 2014.)
Nanoscale, 2014, 6, 10486–10494 | 10491
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View Article Onlineinfrared light (NIR) triggered release, as shown in Fig. 8. Such a
photothermal release has been facilitated by the nanoporous
gold structure. Directional movement was achieved by magnetic
guidance. The incorporation of the nanoporous gold segment
led to a nearly 20 fold increase in the active surface area
(compared to common gold nanowires) and to a high loading
capacity of 13.4 mg mg1 doxorubicin.
Recently developed ultrasound triggered tubular micro-
bullets are extremely promising for addressing the challenges of
limited tissue penetration of therapeutic particles, i.e., directed
drug delivery into diseased tissue (Fig. 9A).30 Such powerful
microbullets, developed by Esener and Wang,30 rely on Acoustic
Droplet Vaporization (ADV) for propulsion of peruorocarbon-
loaded conical-tube microbullets (MB) for penetration into
targeted tissue to provide a remarkable force suﬃcient for
penetrating and deforming cellular tissue for potential targeted
drug delivery and precision nanosurgery. This highly eﬃcient,
powerful and scalable propulsion technique utilizes ultrasound
to vaporize biocompatible fuels (i.e., peruorocarbon PFC
emulsions), conned within the interior of a micromachine, for
an ultrahigh velocity of over 6 m s1 (i.e., approximately 100
times faster than common micromachines). Such ‘bullet-like’
propulsion induces suﬃcient thrust for deep tissue penetration
and deformation for potential targeted drug delivery andFig. 9 (A) Computer-aided graphic (graphics on the left) and the
corresponding experimental images of PFH-loaded MBs (a) pene-
trating, (b) cleaving, and (c) expanding tissue following an US pulse
signal. All images were taken sequentially at a frame rate of 10 000 fps
and 10 objective. US pulses of 44 ms/1.6 MPa were used for (a) and (b)
and short pulses of 4.4 ms/3.8 MPa were used for (c). Dotted circles and
solid arrows are used to indicate the MB's position, while curvilinear
dotted lines outline the tissue. (Reproduced from ref. 30, Wiley 2012.)
(B) Optical microscope image of a HeLa cell containing several gold–
ruthenium nanomotors. Arrows indicate the trajectories of the nano-
motors, and the solid white line shows the propulsion. Near the center
of the image, a spindle of several nanomotors is spinning. Inset:
electron micrograph of a gold–ruthenium nanomotor. The scattering
of sound waves from the two ends results in propulsion. (Reproduced
from ref. 68, Wiley 2014).
10492 | Nanoscale, 2014, 6, 10486–10494precision nanosurgery. By adjusting the level of propulsion
force, diﬀerent depths in the tissue can be reached. Such a
‘bullet-like’ carrier must also have the capability of carrying a
large therapeutic payload.
The US-triggered microbullet propulsion strategy is expected
to have a tremendous impact on diverse biomedical applica-
tions, e.g., targeted drug delivery, circulating biolistics, micro-
tissue and artery-cleaning/removal schemes, precision nano-
surgery, or cancer surgery. Mallouk's group also demonstrated
recently the ultrasonic propulsion of rod-shaped nanomotors
inside living HeLa cells (Fig. 9B).68 These nanomotors can
attach strongly to the external surface of the cells, and are
readily internalized by incubation with the cells for periods
longer than 24 h. The intracellular propulsion did not involve
any chemical fuel and the HeLa cells remained viable. Such
developments hold great promise for future in vivo studies of
the synthetic nanomotors.
Conclusions
This review has discussed recent advances in man-made
nanomotors towards controlled drug delivery applications.
Considerable progress has been made over the past decade in
designing a variety of micro/nanomotors for diverse biomedical
applications and strategies for the transport and release of
therapeutic agents. As our understanding of the design and
operation of nanomotors expands, it becomes feasible to utilize
the new capabilities of these machines for practical biomedical
applications. With increased power and functionality, future
micro/nanomachines are expected to performmore demanding
biomedical tasks and benet diﬀerent drug delivery applica-
tions. While key challenges remain prior to applying these
nanomotors for in vivo targeted drug delivery, these recent
developments advance this objective one step closer to a
futuristic nanomachine suitable for improved delivery of ther-
apeutic agents in the body.
Diﬀerent research teams are currently exploring several
routes for realizing future nanomotor-based drug delivery. In
order to improve the delivery eﬃciency, it is essential to explore
the attachment of drug carriers to nanomotors through chem-
ical or biological linkers that are sensitive to the tumor micro-
environment (e.g., protease enzyme and acidity). Such a
mechanism will allow for a more accurate localized drug
delivery to the target site using drug-loaded particles powered
by external magnetic or ultrasound elds. Improved cellular
uptake could be achieved by the incorporation of an appropriate
ligand. The combination of multiple functions can lead to more
eﬀective operation and this would require the assembly of
multiple nano-objects. In particular, incorporating therapeutic
or diagnostic entities in the same nanomachine would create
theranostic vehicles. Additional eﬀorts should be devoted
towards developing high-performance nanomotor locomotion
based on in situ fuel sources and alternate powering schemes,
oﬀering signicant thrust for overcoming the large drag (asso-
ciated with the presence of the blood cells) and for improving
tissue penetration. Future eﬀorts will involve the development
of intelligent logic-controlled nanomachines69 toward smartThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinedrug-delivery applications. Further attention should be given to
the biocompatibility of drug-delivery nanomotors, and partic-
ularly to common metallic constituents such as Ni, Ag, or Pt.
Lastly, the biodegradability (self-destruction) or removal of
nanomotors from the body aer completing their delivery
mission needs further consideration.
The new generation of nanomachine platforms holds even
greater promise to improve the treatment of diseases. While the
eld of nanomachines has been moving at a very rapid pace,
such devices have translated gradually into clinical practice.
The potential biomedical applications of nanomotors, e.g.,
nanosurgery or biopsy, extend beyond those discussed in this
article and might be limited only by our collective imagination.
As research moves toward developing smaller and multifunc-
tional devices, larger multidisciplinary teams, and eﬀective
communication between various disciplines, are needed for
success. With such collaborative eﬀorts we envision that
synthetic nanomotors would provide a new and unique
approach to rapidly delivering drug carriers to predetermined
destinations. Despite major challenges, the most exciting
prospect of nanomachines is the nearly limitless possibilities
for the treatment of diseases, towards the realization of Asi-
mov's 1966 microscopic submarine.Acknowledgements
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